<html xmlns:mims="http://www.mims.com"><head><link type="text/css" href="css/redmond/jquery-ui-1.8.6.custom.css" rel="stylesheet" /><link type="text/css" href="css/mims.css" rel="stylesheet" /><script type="text/javascript" src="scripts/jquery-1.4.4.min.js"></script><script type="text/javascript" src="scripts/jquery-ui-1.8.6.custom.min.js"></script><script type="text/javascript" src="scripts/monograph.js"></script></head><body><div id="tabs"><ul><li><a href="#tab-generic">Generic</a></li></ul><div id="tab-generic"><h4 class="subheading"></h4><table class="ui-widget monograph"><tr><td class="monograph-heading ui-widget-content"><span style="font-weight: bold">Dosage</span></td><td class="ui-widget-content"><I>Oral</I><BR><B>Tuberculosis</B><BR><B><I>Adult: </I></B>10 mg/kg daily or 2-3 times wkly. Max: 600 mg/day.

<BR><B><I>Child: </I></B>10-20 mg/kg daily or 2-3 times wkly. Max: 600 mg/day. <BR><B><I>Hepatic impairment: </I></B>Dosage reduction may be necessary. <BR><I>Oral</I><BR><B> Leprosy</B><BR><B><I>Adult: </I></B>600 mg once mthly.
<BR><B><I>Child: </I></B>10-14 yr: 450 mg once mthly; 10 yr: 300 mg once mthly. <BR><B><I>Hepatic impairment: </I></B>Dosage reduction may be necessary. <BR><I>Oral</I><BR><B>Prophylaxis against meningococcal meningitis</B><BR><B><I>Adult: </I></B>600 mg bid for 2 days.
<BR><B><I>Child: </I></B>1-12 yr: 10 mg/kg; 12 mth: 5 mg/kg, doses to be given bid for 2 days.<BR><B><I>Hepatic impairment: </I></B>Dosage reduction may be necessary. <BR><I>Oral</I><BR><B>Prophylaxis against meningitis due to <I>Haemophilus influenzae</I></B><BR><B><I>Adult: </I></B>600 mg daily for 4 days. <BR><B><I>Child: </I></B>1-3 mth: 10 mg/kg/day; &amp;gt;3 mth: 20 mg/kg/day. Doses to be taken once daily for 4 days. Max: 600 mg/day. <BR><B><I>Hepatic impairment: </I></B>Dosage reduction may be necessary. <BR><I>Oral</I><BR><B> Legionnaire''s disease</B><BR><B><I>Adult: </I></B>600-1200 mg daily, in divided doses. May also be given via IV infusion. <BR><B><I>Child: </I></B>&amp;le;1 yr: 5-10 mg/kg bid; 1-18 yr: 10 mg/kg (max: 600 mg) bid. May be given via mouth or IV infusion. <BR><B><I>Hepatic impairment: </I></B>Dosage reduction may be necessary. <BR><I>Oral</I><BR><B> Brucellosis</B><BR><B><I>Adult: </I></B>600-1200 mg daily, in divided doses. May also be given via IV infusion. <BR><B><I>Child: </I></B>&amp;le;1 yr: 5-10 mg/kg bid; 1-18 yr: 10 mg/kg (max: 600 mg) bid. May be given via mouth or IV infusion. <BR><B><I>Hepatic impairment: </I></B>Dosage reduction may be necessary. <BR><I>Oral</I><BR><B>Staphylococcal infections</B><BR><B><I>Adult: </I></B>600-1200 mg daily, in divided doses. May also be given via IV infusion. <BR><B><I>Child: </I></B>&amp;le;1 yr: 5-10 mg/kg bid; 1-18 yr: 10 mg/kg (max: 600 mg) bid. May be given via mouth or IV infusion. <BR><B><I>Hepatic impairment: </I></B>Dosage reduction may be necessary.</td></tr><tr><td class="monograph-heading ui-widget-content"><span style="font-weight: bold">Administration</span></td><td class="ui-widget-content">Should be taken on an empty stomach. (Best taken on an empty stomach 1 hr before or 2 hr after meals.)<br></td></tr><tr><td class="monograph-heading ui-widget-content"><span style="font-weight: bold">Contraindications</span></td><td class="ui-widget-content">Hypersensitivity, jaundice, severe hepatic disease. IM/SC admin. Porphyria. Not to be used for treatment of meningococcal disease.</td></tr><tr><td class="monograph-heading ui-widget-content"><span style="font-weight: bold">Special precautions</span></td><td class="ui-widget-content">Impaired hepatic or renal function. Elderly, malnourished or very young patients. Alcoholic patients. Monitor blood counts and liver function regularly. Body fluids may colour orange-red. Discontinue use if thrombocytopenia or purpura occurs. Pregnancy and lactation. Care should be taken during IV admin to prevent extravasation.</td></tr><tr><td class="monograph-heading ui-widget-content"><span style="font-weight: bold">Adverse reactions</span></td><td class="ui-widget-content">GI disturbances, pseudomembranous colitis (rare), abnormalities of liver function, fatalities in those with liver disorders, influenza-like symptoms, skin reactions, eosinophilia, transient leucopenia, thrombocytopenia, purpura, shock, drowsiness, headache, ataxia, visual disturbances, menstrual irregularities. Reddish coloured urine and tears. IV: Thrombophloebitis; extravasation following local irritation and inflammation.<BR/> <B>Potentially Life-Threatening Adverse Drug Reaction: </B>Hepatitis or shock-like syndrome with hepatic involvement.</td></tr><tr><td class="monograph-heading ui-widget-content"><span style="font-weight: bold">Drug interactions</span></td><td class="ui-widget-content">Increased metabolism of chloramphenicol,  clofibrate, dapsone, digoxin, hexobarbitone, ketoconazole and quinidine. Absorption may be decreased when taken with antacids, anticholinergics, opioids and ketoconazole. Increased metabolism of losartan and its active metabolite, diazepam and nitrazepam. Reduces serum levels of aprepitant, atovaquone, bisoprolol, carvedilol, metoprolol, propanolol, buspirone, bunazosin, diltiazem, nifedipine and verapamil. Increased risk of transplant rejection when used with ciclosporin. Decreases effects of tolbutamide, clofibrate, coumarin anticoagulants, diazepam and oral contraceptives.<BR/> <B>Potentially Hazardous Interaction: </B>May reduce efficacy of corticosteroids in Addison''s disease and induce an addisonian crisis.</td></tr><tr><td class="monograph-heading ui-widget-content"><span style="font-weight: bold">Mechanism of action</span></td><td class="ui-widget-content">Rifampicin has a broad-spectrum bactericidal action which inhibits bacterial RNA synthesis by binding to the &amp;beta; subunit of DNA-dependent RNA polymerase, thus blocking RNA transcription. It is commonly used in the treatment of tuberculosis, leprosy and opportunistic atypical mycobacterial infections.<BR><B>Absorption: </B>Readily absorbed from the GI tract (oral); peak plasma concentrations after 2-4 hr. May be reduced and delayed in the presence of food.<BR><B>Distribution: </B>Body tissues and fluids, CSF (increased during meningitis), crosses the placenta and enters into breast milk. Protein-binding: 84-91%<BR><B>Metabolism: </B>Hepatic; converted to 25-O-desacetylrifampicin.<BR><B>Excretion: </B>Via faeces (60% of the dose).</td></tr><tr><td class="monograph-heading ui-widget-content"><span style="font-weight: bold">Lab Interference</span></td><td class="ui-widget-content">Interferes with colorimetric tests, including bromsulphothalein tests of liver function and bilirubin assays. Erroneous low readings of vitamin B<SUB>12</SUB> and folates may occur.</td></tr><tr><td class="monograph-heading ui-widget-content"><span style="font-weight: bold">MIMS Class</span></td><td class="ui-widget-content">Anti-TB AgentsAntileproticsOther Antibiotics</td></tr><tr><td class="monograph-heading ui-widget-content"><span style="font-weight: bold">ATC Classification</span></td><td class="ui-widget-content">J04AB02 - rifampicin; Belongs to the class of antibiotics. Used in the treatment of tuberculosis.<BR></td></tr></table></div></div></body></html>